Opsumit (macitentan) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

February 2016

ADVERSE REACTIONS

Postmarketing

General disorders and administration site conditions: edema/fluid retention

...

Source: Drugs.com - Labeling Changes - February 1, 2016 Category: Drugs & Pharmacology Source Type: alerts